Pipeline Therapeutics is a company.
Pipeline Therapeutics has raised $112.0M across 2 funding rounds.
Key people at Pipeline Therapeutics.
Pipeline Therapeutics has raised $112.0M in total across 2 funding rounds.
Key people at Pipeline Therapeutics.
Pipeline Therapeutics has raised $112.0M in total across 2 funding rounds.
Pipeline Therapeutics's investors include Buff Gold Ventures, Versant Ventures.
Pipeline Therapeutics Inc., now rebranded as Contineum Therapeutics, Inc., is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing novel oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications with high unmet needs.[1][2][5] The company targets biological pathways linked to clinical impairments in disorders like idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PMS), relapse-remitting multiple sclerosis (RRMS), chronic pain, and major depressive disorder, with key pipeline candidates including PIPE-791 (an LPA1 receptor antagonist in Phase 1 for IPF and PMS) and PIPE-307 (a selective M1 receptor inhibitor in Phase 2 for RRMS and planned for depression).[2] It serves patients with these debilitating conditions by aiming to create precision small molecules that modulate innate pathways to restore function and alter disease progression, building growth momentum through clinical advancements, a name change in December 2023 to reflect pipeline expansion into fibrotic diseases, and going public in April 2024 under CEO Carmine Stengone.[1][2]
Founded in 2017 in California as a biotechnology firm specializing in small molecule neuroregeneration therapies, Pipeline Therapeutics evolved from a focus on neuroscience to a broader NI&I portfolio.[5][6] The company rebranded to Contineum Therapeutics in December 2023 to signify its "continuous dedication to scientific discovery" and expansion into inflammation, immunology, and fibrotic diseases like IPF, marking a pivotal moment in its development.[2] Led by CEO Carmine Stengone, this shift built on early traction in internally developed programs targeting validated mechanisms such as LPA1 and M1 receptors, positioning it as a nimble player advancing multiple clinical indications.[2]
Contineum rides the wave of precision medicine in NI&I, where small molecule modulators address unmet needs in chronic neurology, inflammation, and fibrosis—markets driven by aging populations, rising disease prevalence, and demand for disease-modifying therapies beyond symptom management.[2] Timing aligns with advances in receptor-specific targeting (e.g., LPA1, M1), fueled by market forces like post-pandemic immunology focus and fibrosis breakthroughs, positioning the company to influence the ecosystem through clinical data that could validate these pathways for follow-on innovations.[2] As a public clinical-stage player, it contributes to biotech's shift toward nimble, multi-asset firms accelerating from discovery to trials amid venture funding constraints.[1][2]
Contineum is poised for Phase 2 readouts and potential partnerships as PIPE-307 and PIPE-791 advance, with trends like AI-driven drug design and combo therapies in NI&I shaping its path toward approvals in high-value indications like MS and IPF.[2] Its influence may grow via milestone-driven value inflection, expanding the neuroregeneration toolkit and exemplifying how focused biotechs evolve to tackle intertwined disease mechanisms—echoing its origins in targeted small molecules now broadened for patient impact.[2]
Pipeline Therapeutics has raised $112.0M across 2 funding rounds. Most recently, it raised $80.0M Series C in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2021 | $80.0M Series C | Buff Gold Ventures, Versant Ventures | |
| Dec 1, 2019 | $32.0M Series B | Buff Gold Ventures, Versant Ventures |
